Veracyte Announces Third Quarter 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Wall St futures pause after AI rally, focus on Mideast tensions
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Veracyte (VCYT) to See Possible Medicare Payment Cut; Leerink Partners Cuts Price Target to $11
November 6, 2015 8:24 AM ESTLeerink Partners maintained an Outperform rating on Veracyte, Inc (NASDAQ: VCYT), and cut the price target to $11.00 (from $13.00), following the company's 3Q earnings report. VCYT reported Q3 revenue of $12.3M, slightly below the Streets $12.6M. VCYT noted some additional wins with Blues plans in the... More
Sanofi (SNY) Will Outline Long-Term Roadmap; Sees Sales CAGR at 3% - 4% from 2015 -20
November 6, 2015 6:25 AM ESTSanofi (NYSE: SNY) will host an Investor Relations seminar today ('Meet Sanofi Management') at which it will set out its strategic roadmap for the period 2015-2020 and its ambition to become the pre-eminent diversified global healthcare company. Through a process of refocusing and reshaping the organisation and investing in key launches and businesses, Sanofi expects to deliver a sales compound annual growth rate (CAGR) of between +3% and +4%4 over 2015-2020, with a target of mid-single digit... More
Veracyte (VCYT) Tops Q3 EPS by 1c
November 5, 2015 5:28 PM ESTVeracyte (NASDAQ: VCYT) reported Q3 EPS of ($0.32), $0.01 better than the analyst estimate of ($0.33). Revenue for the quarter came in at $12.3 million versus the consensus estimate of $12.72 million.
For earnings history and earnings-related data on Veracyte (VCYT) click here.
... More